**All Interactions with Maraviroc (Selzentry)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Maraviroc** | **Effect on Drug Levels** | **Effect on Maraviroc Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Atazanavir[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (ATV)(Reyataz) | 300 mg QD with 100 mg ritonavir QD | 300 mg BID | - | Maraviroc AUC: increased 388%; Cmax: increased 167%; Cmin: increased 567% | Increased maraviroc effects | Inhibition of CYP450 3A4 by atazanavir/ritonavir | Decrease maraviroc dose to 150 mg BID |
| Atazanavir[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (ATV)(Reyataz) | 400 mg QD | 300 mg BID | - | Maraviroc AUC: increased 257%; Cmax: increased 109%; Cmin: increased 319% | Increased maraviroc effects | Inhibition of CYP450 3A4 by atazanavir | Decrease maraviroc dose to 150 mg BID |
| Darunavir[631](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#631)  (DRV)(Prezista) | 600 mg BID with 100 mg ritonavir BID | 150 mg BID | - | Maraviroc AUC: increased 4.05 fold; Cmax: increased 2.29 fold; Cmin: increased 8.0 fold | Increased maraviroc effects | Inhibition of CYP450 3A4 by darunavir/ritonavir | No dose adjustment necessary; utilize maraviroc 150 mg BID when combined with darunavir/ritonavir |
| Darunavir[565](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#565)  (DRV)(Prezista) | 800/100 mg BID | 300 mg QD | Not studied | Maraviroc Cmin: increased 16%; Cmax: no significant change (when compared to maraviroc 300 mg BID without darunavir/ritonavir in separate control arm) | - | Inhibition of CYP450 3A4 by darunavir/ritonavir | No dose adjustment necessary |
| Efavirenz[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (EFV)(Sustiva) | 600 mg QD | 100 mg BID | - | Maraviroc AUC: decreased 45%; Cmax: decreased 51%; Cmin: decreased 45% | Decreased maraviroc effects | Induction of CYP450 3A4 by efavirenz | Increase maraviroc dose to 600 mg BID |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Maraviroc** | **Effect on Drug Levels** | **Effect on Maraviroc Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Etravirine[1](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#1)  (ETR)(Intelence) | 200 mg BID | 300 mg BID | No significant change | Maraviroc AUC: decreased 53%; Cmax: decreased 60%; Cmin: decreased 39% | - | Induction of CYP450 3A4 by etravirine | Increase maraviroc to 600 mg BID when used with etravirine |
| Etravirine[631](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#631)  (ETR)(Intelence) | 200 mg BID | 300 mg BID | - | Maraviroc AUC: decreased 53%; Cmax: decreased 60%; Cmin: decreased 39% | Decreased maraviroc effects | Induction of CYP450 3A4 by etravirine | Increase maraviroc to 600 mg BID when combined with etravirine |
| Etravirine[1](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#1)  (ETR)(Intelence) | 200 mg BID with darunavir/ritonavir 600/100 mg BID | 300 mg BID | No significant change on etravirine, darunavir or ritonavir pharmacokinetics | Maraviroc AUC: increased 210%; Cmax: increased 77%; Cmin: increased 430% | Increased maraviroc effects | Inhibition of CYP450 3A4 by darunavir/ritonavir | Decrease maraviroc to 150 mg BID |
| Etravirine[631](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#631)  (ETR)(Intelence) | 200 mg BID with darunavir/ritonavir 600/100 mg BID | 150 mg BID | - | Maraviroc AUC: increased 3.10 fold; Cmax: increased 1.76 fold; Cmin: increased 5.27 fold | Increased maraviroc effects | - | No dose adjustment necessary; utilize maraviroc 150 mg BID when combined with etravirine AND darunavir/ritonavir |
| Fosamprenavir[657](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#657)  (FPV)(Lexiva) | 1400 mg QD with ritonavir 100 mg QD | 300 mg QD | Amprenavir AUC: decreased 30%; Cmax: decreased 29%; Cmin: decreased 15%; Ritonavir AUC: decreased 30%; Cmax: decreased 39%; Cmin: increased 2.66 fold | Maraviroc AUC: increased 2.26 fold; Cmax: increased 1.45 fold; Cmin: increased 1.80 fold | - | - | Dose adjustment not established |
| Fosamprenavir[657](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#657)  (FPV)(Lexiva) | 700 mg BID with ritonavir 100 mg BID | 300 mg BID | Amprenavir AUC: decreased 35%; Cmax: decreased 34%; Cmin: decreased 36% Ritonavir AUC: decreased 34%; Cmax: decreased 39%; Cmin: decreased 14% | Maraviroc AUC: increased 2.49 fold; Cmax: increased 1.52 fold; Cmin: increased 4.75 fold | - | - | Dose adjustment not established. |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Maraviroc** | **Effect on Drug Levels** | **Effect on Maraviroc Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ketoconazole[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (Nizoral) | 400 mg QD | 100 mg BID | - | Maraviroc AUC: increased 400%; Cmax: increased 238%; Cmin: increased 275% | Increased maraviroc effects | Inhibition of CYP450 3A4 by ketoconazole | Reduce maraviroc dose to 150 mg BID when used with ketoconazole |
| Lopinavir/ritonavir[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (LPV/r)(Kaletra) | 400 mg/100 mg BID | 300 mg BID | - | Maraviroc AUC: increased 295%; Cmax: increased 97%; Cmin: increased 824% | Increased maraviroc effects | Inhibition of CYP450 3A4 by lopinavir/ritonavir | Reduce maraviroc dose to 150 mg BID |
| Lopinavir/ritonavir[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (LPV/r)(Kaletra) | 400 mg/100 mg BID with 600 mg efavirenz QD | 300 mg BID | - | Maraviroc AUC: increased 153%; Cmax: increased 25%; Cmin: increased 529% | Increased maraviroc effects | Inhibition of CYP450 3A4 by lopinavir/ritonavir | Decrease maraviroc dose to 150 mg BID |
| Nevirapine[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (NVP)(Viramune) | 200 mg BID | 300 mg | - | Maraviroc Cmax: increased 54% | - | - | Increase maraviroc dose to 300 mg BID |
| Raltegravir[535](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#535)  (RAL)(Isentress) | 400 mg Q12H | 300 mg Q12H | Raltegravir AUC: decreased 37%; Cmin: decreased 28%; Cmax: decreased 33% | Maraviroc Cmin: decreased 21%; Cmax: decreased 20% | - | - | No dose adjustment necessary |
| Rifampin[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (Rifampicin)(Rifadin) | 600 mg QD | 100 mg BID | - | Maraviroc AUC: decreased 63%; Cmax: decreased 67%; Cmin: decreased 78% | Decreased maraviroc effects | Induction of CYP450 3A4 by rifampin | Do not coadminister  *Alternative Agents*:  **Rifabutin** |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Maraviroc** | **Effect on Drug Levels** | **Effect on Maraviroc Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ritonavir[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (RTV)(Norvir) | 100 mg BID | 100 mg BID | - | Maraviroc AUC: increased 161%; Cmin: increased 355%; Cmax: increased 28% | Increased maraviroc effects | Inhibition of CYP450 3A4 by ritonavir | - |
| Saquinavir[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (SQV)(Fortovase, Invirase) | 1000 mg BID with ritonavir 100 mg BID | 100 mg BID | - | Maraviroc AUC: increased 877%; Cmax: increased 378%; Cmin: increased 1030% | Increased maraviroc effects | Inhibition of CYP450 3A4 by saquinavir/ritonavir | Decrease maraviroc dose to 150 mg BID |
| Saquinavir[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (SQV)(Fortovase, Invirase) | Saquinavir 1000 mg BID with 100 mg ritonavir BID with 600 mg efavirenz QD | 100 mg BID | - | Maraviroc AUC: increased 400%; Cmax: increased 126%; Cmin: increased 742% | Increased maraviroc effects | Inhibition of CYP450 3A4 by saquinavir/ritonavir | Decrease maraviroc dose to 150 mg BID |
| Tipranavir[2](http://arv.ucsf.edu/insite?page=ar-00-02&param=2&post=4#2)  (TPV)(Aptivus) | 500 mg BID with 200 mg ritonavir BID | 150 mg BID | - | Maraviroc Cmin: increased 80%; | - | - | Increase maraviroc dose to 300 mg BID |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 1: | Davis J, Scholler-Gyure M, Kakuda TN, et al. An open randomized two period crossover study in 2 cohorts to investigate the effect of steady state TMC125 and the combination of TMC125/DRV/r on the steady state pharmacokinetics of oral maraviroc in healthy subjects [abstract P 4.3/02]. 11th European AIDS Conference; 2007 October 24-27; Madrid, Spain. |
| 2: | Selzentry [package insert]. New York, NY: Pfizer, Inc.; August 2012. |
| 535: | Andrews E, Glue P, Fang J, et al. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Brit J Clin Pharmacol 2010; 69: 51-7. |
| 565: | Taylor S, Dufty N, Watson J, et al. MVC 300 mg once daily + DRV/RTV 800/100 mg once daily provides MVC trough concntrations comparable to trough concentrations in HIV-1 patients taking MVC 300 mg twice daily + TVD: implications for phase 3 studies [paper #636]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-March 2, 2011. Boston, MA. |
| 631: | Kakuda TN, Abel S, Davis J, et al. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug intaraction trials. Antimicrob Agent Chemother 2011; 55: 2290-96. |
| 657: | Vourvahis M, Plotka A, Mendes da Costa L, et al. Pharmacokinetic interaction between maraviroc and fosamprenavir/ritonavir: an open lbael, fixed sequence study in healthy volunteers [abstract P 12]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 2012. Barcelona, Spain. |